Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Jasper Therapeutics appointed Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President of Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President of Clinical Development — its first leadership additions following the merger with Kira Pharmaceuticals. Pitt brings more than 25 years of regulatory and medical affairs experience spanning the FDA's CDER, Aiolos Bio, Horizon Therapeutics, and Viela Bio; Liu joins after over a decade at Sanofi leading late-stage clinical development in rare renal and metabolic disorders.
Key figures
- Vesting terms
- 4 years, 25% cliff at one-year anniversary, then 1/48th monthly
- Option exercise price
- 0.6328
- Inducement options granted
- 243000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.